News
-
-
PRESS RELEASE
Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Under Review
First Berlin Equity Research updates rating and price target for Jaguar Health Inc (ISIN: US47010C8055) to 'Under Review' due to recent restructuring steps and ongoing liquidity concerns, while recognizing positive clinical developments -
-
PRESS RELEASE
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
Jaguar Health, Inc. provides promising results on crofelemer for pediatric intestinal failure patients at ESPGHAN Meeting. Liquid oral crofelemer shows significant reductions in parenteral support requirements normalized to body weight -
-
PRESS RELEASE
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
Jaguar Health, Inc. continues global development program for crofelemer in pediatric intestinal failure patients with MVID and SBS-IF. Special Stock Dividend and conversion of Preferred Stock announced to benefit stockholders -
-
PRESS RELEASE
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar submits NADA for Canalevia-CA1 to FDA for CID in dogs, reporting positive results in study. Crofelemer effectively treats chemotherapy-induced diarrhea -
-
PRESS RELEASE
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
Jaguar Health, Inc. to explore strategic alternatives maximizing stockholder value. Updates on crofelemer program for rare intestinal failure diseases by CEO Lisa Conte at Life Sciences Virtual Investor Forum on June 24, 2026
